• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Indications for Neoadjuvant Systemic Therapy for Breast Cancer.

作者信息

Gallagher Kristalyn K, Ollila David W

机构信息

Department of Surgery, Division of Surgical Oncology, The University of North Carolina at Chapel Hill, 170 Manning Drive, CB 7213, 1150 Physicians Office Building, Chapel Hill, NC 27599-7213, USA.

Department of Surgery, Division of Surgical Oncology, The University of North Carolina at Chapel Hill, 170 Manning Drive, CB 7213, 1150 Physicians Office Building, Chapel Hill, NC 27599-7213, USA.

出版信息

Adv Surg. 2019 Sep;53:271-292. doi: 10.1016/j.yasu.2019.04.013. Epub 2019 Jun 6.

DOI:10.1016/j.yasu.2019.04.013
PMID:31327452
Abstract
摘要

相似文献

1
Indications for Neoadjuvant Systemic Therapy for Breast Cancer.乳腺癌新辅助全身治疗的适应证
Adv Surg. 2019 Sep;53:271-292. doi: 10.1016/j.yasu.2019.04.013. Epub 2019 Jun 6.
2
Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.分子亚型作为乳腺癌患者新辅助化疗反应的预测指标
Indian J Cancer. 2017 Oct-Dec;54(4):652-657. doi: 10.4103/ijc.IJC_238_17.
3
Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.采用新辅助治疗方法评估乳腺癌患者的新型疗法。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:47-55. doi: 10.1200/EDBK_200719.
4
Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.新辅助化疗可提高早期可手术乳腺癌的保乳手术率。
Hong Kong Med J. 2017 Jun;23(3):251-7. doi: 10.12809/hkmj164972. Epub 2017 May 9.
5
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.浸润性肿瘤 CD8/FOXP3 淋巴细胞比值预测侵袭性乳腺癌新辅助化疗的治疗反应。
Br J Surg. 2016 Jun;103(7):845-54. doi: 10.1002/bjs.10127. Epub 2016 Mar 8.
6
Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.乳腺癌新辅助化疗分子亚型与疗效的相关性及其预后因素分析
Pathol Res Pract. 2018 Aug;214(8):1166-1172. doi: 10.1016/j.prp.2018.06.010. Epub 2018 Jun 19.
7
[Not Available].[无可用内容]
Bull Cancer. 2016 Jun;103(6 Suppl 1):S76-89. doi: 10.1016/S0007-4551(16)30149-7.
8
Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?多灶性回归是否为新辅助化疗和保乳治疗后现代时代同侧乳腺癌复发的危险因素？
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):869-876. doi: 10.1016/j.ijrobp.2019.03.012. Epub 2019 Mar 15.
9
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.ERBB2 阳性或三阴性乳腺癌患者低淋巴结阳性率与新辅助化疗后乳腺病理完全缓解的相关性。
JAMA Surg. 2018 Dec 1;153(12):1120-1126. doi: 10.1001/jamasurg.2018.2696.
10
Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.早期乳腺癌的新辅助治疗：当前实践、争议及未来方向
Oncology (Williston Park). 2015 Nov;29(11):828-38.

引用本文的文献

1
Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.通过治疗驱动的体细胞变异选择来鉴定乳腺癌化疗反应的候选介质。
Breast Cancer Res Treat. 2020 Oct;183(3):607-616. doi: 10.1007/s10549-020-05836-7. Epub 2020 Jul 30.
2
Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗HER2阳性乳腺癌患者的临床疗效
Medicine (Baltimore). 2019 Sep;98(38):e17262. doi: 10.1097/MD.0000000000017262.